the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
Official Title A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Principal Investigator Luke, Jason
Brief Summary The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.
Gender All
Ages 18 Years
Enrollment 131
Accepts Healthy Volunteers No
Lead Sponsor MacroGenicsIndustry
Collaborator
Study Design
Study Phase Phase 1
Study Type Interventional
Contact Name Bartosz Chmielowski, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Advanced Solid Tumors
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI